Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Because P-5-P does not require enzymatic conversion in the liver, it is immediately available for use in the transsulfuration pathway and does not carry the same toxicity risks associated with high-dose pyridoxine
In November 2023, Chinese biotech company Chengyi Bio and AstraZeneca reached an exclusive licensing agreement of more than US$2 billion for the small molecule GLP-1R agonist ECC-5004
The medication carries a risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Zhang, Z., Morstein, J., Ecker, A
not investment advice
US$ 29.30
US$ 29.96
US$ 28.79
US$ 20.55
